Axiom Investors LLC DE Has $3.83 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Axiom Investors LLC DE cut its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 4.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 43,904 shares of the biotechnology company’s stock after selling 1,920 shares during the quarter. Axiom Investors LLC DE’s holdings in Blueprint Medicines were worth $3,829,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Quarry LP bought a new stake in shares of Blueprint Medicines in the third quarter worth $32,000. R Squared Ltd bought a new stake in shares of Blueprint Medicines in the 4th quarter valued at about $51,000. Asset Management One Co. Ltd. bought a new stake in shares of Blueprint Medicines in the 4th quarter valued at about $88,000. Van ECK Associates Corp increased its stake in shares of Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 363 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of Blueprint Medicines during the third quarter worth about $108,000.

Insider Buying and Selling

In related news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $102.28, for a total transaction of $511,400.00. Following the transaction, the director now directly owns 157,557 shares in the company, valued at approximately $16,114,929.96. The trade was a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ariel Hurley sold 2,250 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $100.00, for a total transaction of $225,000.00. Following the completion of the sale, the insider now directly owns 14,967 shares of the company’s stock, valued at $1,496,700. The trade was a 13.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,608 shares of company stock worth $3,319,587. 4.21% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on BPMC shares. HC Wainwright restated a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Stephens reissued an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a research note on Thursday, January 2nd. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. lifted their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Two analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Blueprint Medicines currently has an average rating of “Moderate Buy” and an average price target of $124.95.

Blueprint Medicines Stock Performance

Shares of BPMC stock opened at $88.51 on Tuesday. Blueprint Medicines Co. has a 12 month low of $80.68 and a 12 month high of $121.90. The firm has a market capitalization of $5.66 billion, a PE ratio of -81.95 and a beta of 0.58. The firm has a fifty day simple moving average of $97.70 and a two-hundred day simple moving average of $94.07. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.